Ibrutinib is a small-molecule covalent inhibitor of Bruton tyrosine kinase (BTK) and has been approved by the Food and Drug Administration (FDA) for the treatment of lymphoma, including chronic lymphocytic leukemia43,44. Here, BTK is linked to lymphoma.